Jones “Woody” Bryan Joins UroGen Pharma as Senior Vice President of Business Development
“We are very excited to have someone of Woody’s caliber join our team and help us fully realize the burgeoning opportunity of lead drug candidates, UGN-101 and UGN 102 and our RTGel™ technology platform, to potentially provide novel therapies for patients worldwide,” said Ron Bentsur, Chief Executive Officer of UroGen. “Woody’s extensive experience in strategy and business development, as well as his long-standing relationships with key industry players, will be important as we focus on executing our business development strategy.”
“I believe UroGen has the transformative science, encouraging data, dedicated team of industry veterans, and strong financial position to change the treatment paradigm in uro-oncology,” said Dr. Bryan. “I look forward to helping more patients and creating added value for shareholders by building on UroGen’s existing foundation with new, innovative partnerships.”
Dr. Bryan previously served as SVP of Business Development at Sucampo Pharmaceuticals, Inc., where he spearheaded the business development effort for its recent acquisition by Mallinckrodt Pharmaceuticals for $1.2 billion earlier this year. In this role, he also led the evaluation of several in-licensing opportunities and acquisition of multiple assets. Prior to joining Sucampo, Dr. Bryan was SVP of Business Development at Lupin Pharmaceuticals, Inc. His previous roles include VP of Business Development, Licensing at Supernus Pharmaceuticals, Inc. and VP of Business Development, Licensing and Project Management at Shire Laboratories, Inc. (a Division of Shire Pharmaceuticals Group). He is currently a Board Member of Afecta Pharma and a Board Member and past Chairman of Clemson University’s Spiro Institute of Entrepreneurial Leadership and Innovation. Dr. Bryan holds a B.S. in zoology from Clemson University, a Ph.D. in pharmaceutical sciences from the Medical University of South Carolina, and an Executive Management Certificate from the University of North Carolina at Chapel Hill Kenan-Flagler School of Business.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 (mitomycin gel for urothelial instillation), formerly known as MitoGel®, and UGN-102 (mitomycin gel for intravesical instillation), formerly known as VesiGel™, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered in Ra’anana, Israel with U.S. headquarters in New York.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to regulatory approval and commercial prospects of the product candidates in UroGen Pharma’s pipeline, UroGen Pharma’s ability to change the treatment paradigm in uro-oncology, UroGen Pharma’s ability to establish new, innovative partnerships, and the general effects of Dr. Bryan joining UroGen Pharma, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials and potential complications thereof; the ability to obtain and maintain regulatory approval; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen Pharma’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; and UroGen Pharma’s ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of the final prospectus for UroGen Pharma’s public offering of securities in the United States filed with the SEC on January 22, 2018 and other filings that UroGen Pharma makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen Pharma’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen Pharma as of the date of this release.
Kate Bechtold, 914-552-0456
Director, Corporate Communications & Investor Relations
Source: UroGen Pharma Ltd.